305 related articles for article (PubMed ID: 35277357)
1. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
McGarry ME; Gibb ER; Oates GR; Schechter MS
Paediatr Respir Rev; 2022 Jun; 42():35-42. PubMed ID: 35277357
[TBL] [Abstract][Full Text] [Related]
2. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
McGarry ME; McColley SA
Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563
[TBL] [Abstract][Full Text] [Related]
3. Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities.
Montemayor K; Jain R
Med Clin North Am; 2022 Nov; 106(6):1001-1012. PubMed ID: 36280328
[TBL] [Abstract][Full Text] [Related]
4. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
5. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
6. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
7. Emerging medicines to improve the basic defect in cystic fibrosis.
Fajac I; Sermet-Gaudelus I
Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
[TBL] [Abstract][Full Text] [Related]
8. CFTR Modulators: From Mechanism to Targeted Therapeutics.
Yeh HI; Sutcliffe KJ; Sheppard DN; Hwang TC
Handb Exp Pharmacol; 2024; 283():219-247. PubMed ID: 35972584
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
10. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
[TBL] [Abstract][Full Text] [Related]
11. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
12. Mutation-specific therapies and drug repositioning in cystic fibrosis.
Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
14. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
17. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.
Cao L; Wu Y; Gong Y; Zhou Q
Eur J Med Chem; 2024 Feb; 265():116120. PubMed ID: 38194776
[TBL] [Abstract][Full Text] [Related]
18. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.
Southern KW; Castellani C; Lammertyn E; Smyth A; VanDevanter D; van Koningsbruggen-Rietschel S; Barben J; Bevan A; Brokaar E; Collins S; Connett GJ; Daniels TWV; Davies J; Declercq D; Gartner S; Gramegna A; Hamilton N; Hauser J; Kashirskaya N; Kessler L; Lowdon J; Makukh H; Martin C; Morrison L; Nazareth D; Noordhoek J; O'Neill C; Owen E; Oxley H; Raraigh KS; Raynal C; Robinson K; Roehmel J; Schwarz C; Sermet I; Shteinberg M; Sinha I; Takawira C; van Mourik P; Verkleij M; Waller MD; Duff A
J Cyst Fibros; 2023 Jan; 22(1):17-30. PubMed ID: 36916675
[TBL] [Abstract][Full Text] [Related]
19. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
20. Impact of
Meoli A; Eickmeier O; Pisi G; Fainardi V; Zielen S; Esposito S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
